JP7249492B2 - Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 - Google Patents

Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 Download PDF

Info

Publication number
JP7249492B2
JP7249492B2 JP2020511529A JP2020511529A JP7249492B2 JP 7249492 B2 JP7249492 B2 JP 7249492B2 JP 2020511529 A JP2020511529 A JP 2020511529A JP 2020511529 A JP2020511529 A JP 2020511529A JP 7249492 B2 JP7249492 B2 JP 7249492B2
Authority
JP
Japan
Prior art keywords
glp
peptibody
seq
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531030A5 (enExample
JP2020531030A (ja
Inventor
パン，クラーク
ノートン，アンジェラ
シュトラック－ローグ，ベッティーナ
スゥン，カァフォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceuticals USA Inc
Original Assignee
Takeda Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals USA Inc filed Critical Takeda Pharmaceuticals USA Inc
Publication of JP2020531030A publication Critical patent/JP2020531030A/ja
Publication of JP2020531030A5 publication Critical patent/JP2020531030A5/ja
Application granted granted Critical
Publication of JP7249492B2 publication Critical patent/JP7249492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020511529A 2017-08-22 2018-08-21 Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 Active JP7249492B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762548601P 2017-08-22 2017-08-22
US62/548,601 2017-08-22
US201862621144P 2018-01-24 2018-01-24
US62/621,144 2018-01-24
US201862659394P 2018-04-18 2018-04-18
US62/659,394 2018-04-18
PCT/US2018/047171 WO2019040399A1 (en) 2017-08-22 2018-08-21 GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS

Publications (3)

Publication Number Publication Date
JP2020531030A JP2020531030A (ja) 2020-11-05
JP2020531030A5 JP2020531030A5 (enExample) 2021-07-26
JP7249492B2 true JP7249492B2 (ja) 2023-03-31

Family

ID=65440156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511529A Active JP7249492B2 (ja) 2017-08-22 2018-08-21 Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用

Country Status (9)

Country Link
US (2) US20200199192A1 (enExample)
EP (1) EP3672621A4 (enExample)
JP (1) JP7249492B2 (enExample)
CN (1) CN111182916A (enExample)
AU (1) AU2018321841A1 (enExample)
BR (1) BR112020003736A2 (enExample)
CA (1) CA3071966A1 (enExample)
TW (1) TW201920242A (enExample)
WO (1) WO2019040399A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355187A1 (en) * 2018-10-24 2021-11-18 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CA3245162A1 (en) * 2022-03-03 2023-09-07 Univ Pennsylvania Viral vectors encoding fusion proteins, GLP-2 receptor agonists, and their uses in the treatment of short bowel syndrome
WO2024123812A1 (en) * 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025106930A1 (en) * 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025162422A1 (zh) * 2024-01-31 2025-08-07 杭州先为达生物科技股份有限公司 胰高血糖素样肽2衍生物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP2010502195A (ja) 2006-08-31 2010-01-28 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP2014526254A (ja) 2011-09-12 2014-10-06 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
JP2015503554A (ja) 2011-12-30 2015-02-02 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 免疫グロブリンフラグメントを用いた部位特異的ｇｌｐ−２薬物結合体
WO2016108654A1 (ko) 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
KR102825098B1 (ko) * 2017-11-06 2025-06-26 다케다 야쿠힌 고교 가부시키가이샤 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP2010502195A (ja) 2006-08-31 2010-01-28 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP2014526254A (ja) 2011-09-12 2014-10-06 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
JP2015503554A (ja) 2011-12-30 2015-02-02 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 免疫グロブリンフラグメントを用いた部位特異的ｇｌｐ−２薬物結合体
WO2016108654A1 (ko) 2014-12-31 2016-07-07 주식회사 제넥신 Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CA3071966A1 (en) 2019-02-28
EP3672621A1 (en) 2020-07-01
EP3672621A4 (en) 2021-11-24
US20230031280A1 (en) 2023-02-02
JP2020531030A (ja) 2020-11-05
US20200199192A1 (en) 2020-06-25
AU2018321841A1 (en) 2020-02-20
WO2019040399A1 (en) 2019-02-28
BR112020003736A2 (pt) 2020-09-08
TW201920242A (zh) 2019-06-01
CN111182916A (zh) 2020-05-19

Similar Documents

Publication Publication Date Title
JP7249492B2 (ja) Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
JP6722175B2 (ja) 代謝障害を処置するための組成物及びその使用方法
CN103649127B (zh) 用于代谢病症和疾病治疗的组合物、应用和方法
JP2022046520A (ja) ＩＬ－２２ポリペプチド及びＩＬ－２２Ｆｃ融合タンパク質並びに使用方法
TWI436776B (zh) Ｆｇｆ２１突變體及其用途
CN111944055B (zh) 一种治疗代谢疾病的融合蛋白
JP6633108B2 (ja) 脂肪組織の集積を処置するための組成物および方法
TWI835773B (zh) 組合物及使用方法
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
JP2021517584A (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
CN106687478A (zh) 新的抗人Tie‑2抗体
AU2017358289A1 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
US20180280474A1 (en) Treatment of bile acid disorders
US20210355187A1 (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
JP2023509189A (ja) Ｒｓｐｏ１タンパク質およびその使用
HK40029773A (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
HK40042173B (zh) 生长分化因子15激动剂化合物及其使用方法
HK1234078B (zh) 新的抗人tie-2抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230126

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230220

R150 Certificate of patent or registration of utility model

Ref document number: 7249492

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350